Hospice Valuation Multiples: Match the Business Scope

Define the business behind the hospice label

A hospice deal may cover one provider, several locations or a company with other services. The label alone does not tell you what is being bought. Before using a multiple, list the businesses that earn the money. Then check which interests the stated price buys.

This matters even when both published amounts are accurate. A whole-company price divided by one segment's earnings does not become a segment acquisition multiple. It combines two different populations. Fixing that mismatch may require information the public record does not provide.

The valuation overview describes the wider process. This guide helps evaluate hospice comparison evidence before using it in an actual assignment. It does not provide a universal hospice range, a price per patient or an automatic premium for the care category.

Map price scope and earnings scope separately

Create two short lists. The first names the entities, sites, assets and ownership interests covered by the price. The second names the services and costs included in the earnings. Compare them directly. A shared company name does not prove that the two lists match.

The financial-statements and cost-reports guide explains why reports with different purposes need reconciliation. Do not choose the largest earnings figure merely because it creates a smaller ratio. Identify its scope first, then decide whether it belongs in the comparison.

Read the segment footnote before using the subtotal

Enhabit's 2025 Form 10-K reports home-health and hospice segment measures. Its hospice footnote says Segment Adjusted EBITDA excludes corporate overhead not allocated to reportable segments. The local-looking subtotal therefore differs from the company's complete consolidated measure. This is historical issuer evidence, not a hospice-only transaction benchmark. (Source: Enhabit 2025 segment disclosure)

Read the issuer's definition rather than assuming all adjusted measures have identical treatment. SEC guidance also distinguishes required segment information under ASC 280 from other non-GAAP measures. A segment title containing adjusted EBITDA does not, by itself, settle its reporting classification. (Source: SEC questions 104.01–104.03)

The practical question here is narrower than classifying a filing: which costs does the number include? Ask for the reconciliation to the wider organization. Central billing, technology, leadership or other support may sit elsewhere. The actual records determine their treatment; the care segment's name does not.

Know what a hospice cost report can establish

CMS describes its Hospice 1984-2014 dataset as cost and statistical information for free-standing hospice providers. It retains the most precise version of each filed report in that dataset. The reporting provider and period still need to match your question. (Source: CMS hospice cost-report description)

A provider report can help investigate costs and activity without establishing a current transaction price or a whole-company earnings measure. Record the provider identifier, dates and version. Then reconcile the relevant amounts with the seller's accounts. Do not treat a downloadable row as a completed valuation of the business.

If several providers are being purchased, determine which reports cover them and what lies outside those reports. A current ownership chart and location list can expose a missing operation. A numerical total that ties within one report does not prove that the report covers the entire proposed acquisition.

Worked exercise: repair the group comparison

Consider an entirely fictional group with hospice and home-health operations. Assume its proposed operating-business price is $9,000,000. The price covers both operations on the same full-ownership basis. Property, excess cash, debt and contingent consideration are excluded. Every figure is invented; none is a market observation.

Assume annual hospice earnings before unallocated corporate support are $1,200,000. Home-health earnings on the same basis are $800,000. The group incurs $500,000 of recurring corporate support costs, included in neither segment subtotal. All other relevant recurring operating costs are assumed included for this teaching case.

The group reconciliation is $1,200,000 plus $800,000 minus $500,000, or $1,500,000. There is no supported allocation of the purchase price between the two service lines. There is also no supported division of corporate costs between them. Those missing facts are deliberate and remain unknown.

Explain what each resulting ratio actually means

Dividing $9,000,000 by the hospice subtotal produces 7.5. That arithmetic is correct, but describing it as a hospice acquisition multiple is wrong. The numerator buys both operations, while the denominator covers only hospice and still excludes shared corporate costs.

Dividing the price by the combined $2,000,000 subtotal produces 4.5. That calculation matches the two service populations but omits the assumed $500,000 recurring support cost. It is a ratio to combined segment subtotals, not to the complete group earnings used in this exercise.

The six-times result repairs the group calculation; it does not create a hospice-only comparable. It is also not a suggested market factor. The earnings-measure guide helps describe the underlying measure, but definitions cannot supply missing transaction facts.

Resist convenient allocations that lack support

Splitting the group price by revenue share may seem like an easy way to produce a hospice price. It assumes the services have the same link between revenue and value. The fictional facts provide no such evidence. A simple percentage would add a new claim that the exercise cannot support.

The same caution applies to allocating central costs. A defensible allocation needs a stated purpose and evidence for the relevant services. A historical reporting allocation, a standalone replacement budget and a buyer's integration plan answer different questions. Do not interchange them just to complete a comparison table.

IRS internal valuation guidance requires identifying the interest and relevant assumptions and analyzing the supporting information. It does not supply a missing hospice allocation or endorse a mechanical revenue split. (Source: IRS business valuation guidelines)

Use the valuation-methods guide when a market comparison cannot be completed. An incomplete comparable does not force a value conclusion. It identifies which additional evidence or other method the responsible professional should consider for the actual assignment.

Keep hospice operating obligations in the earnings review

A complete financial population still needs a sound operating base. Care mix, staffing, contracted services and continuing support affect costs. The hospice earnings guide shows why identical average daily census can coexist with different care requirements and financial results.

Do not convert census, admissions or patient days directly into a price. These activity measures describe different aspects of the provider. They do not establish patient retention, future eligibility or freedom to change care. Clinical decisions must remain based on the applicable care requirements and individual needs. The hospice diligence guide organizes the supporting review.

The cap-liability guide addresses a separate obligation review. Identify relevant periods and evidence rather than assuming a segment margin resolves a cap exposure. A financial comparison also does not establish enrollment continuity or permission to operate after a proposed ownership change.

Record an honest comparison conclusion

State whether the evidence fits the question, fits only with stated limits, or is incomplete. Explain the reason in a sentence. A group deal may provide useful context without supporting a hospice-only ratio. That finding helps the review. It is not a failure to finish the math.

Retain the source date, transaction stage and any later amendment. Distinguish a completed deal from a proposal or illustrative fairness analysis. If a headline contains maximum contingent consideration, explain the amount and conditions before using it as a numerator. Do not silently equate possible future payment with cash paid at closing.

The hospice sale-price FAQ covers headline terms and seller cash separately. Keep that question distinct from this guide's population test. Confidential provider and financial records should remain within the authorized review process; public comparison research does not justify wider access to patient information.

Common mistakes

The central mistake is pairing a whole-group price with hospice-only earnings. Another is using segment earnings before corporate support while describing the result as a complete operating multiple. These errors can move the apparent ratio in opposite directions, making a copied range especially hard to interpret.

Do not assume that every cost report is a current whole-business profit statement. Match its provider, dates and reporting purpose, then reconcile its limits. Equally, avoid treating a correct spreadsheet sum as proof that each input belongs to the proposed acquisition.

Finally, do not describe the fictional 4.5, six and 7.5 calculations as low, middle and high market observations. They are three descriptions of one invented price using different denominators. Only the group case matches the stated complete earnings scope, and none establishes a hospice-only price.

Summary

Evaluate hospice multiples by matching the purchased population with complete, clearly defined earnings. Read segment footnotes, map provider reports and preserve missing allocations as unknown. A repaired whole-group ratio can be useful without becoming a hospice-only benchmark.

The best comparison record explains both what the evidence supports and what it cannot establish. Use it to direct the next document request or professional analysis. Keep operating obligations, sale terms and seller proceeds visible as related questions that a single ratio cannot resolve.